Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/2003

01-06-2003 | Symposium Series

International conference: Progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK

Authors: Robert C. Rees, R. Adrian Robins, Graham Pawelec, Ludmila Muller, Geng Li, Ian Spendlove

Published in: Cancer Immunology, Immunotherapy | Issue 6/2003

Login to get access

Excerpt

Applying new methods for detecting and quantifying responses to tumour antigens is essential for accurate evaluation of patients undergoing immunotherapy. A good example of these new approaches is MHC tetramer technology, where T cells recognizing a particular MHC-peptide combination can be identified and counted by their binding of labelled tetrameric MHC-peptide complexes. This was illustrated by A. Dodi (London) in patients with chronic myelogenous leukaemia (CML). There is an "ideal" candidate antigen in CML represented by the bcr/abl fusion protein resulting from the presence of the Philadelphia chromosome. Tetramer-positive cells, recognising the HLA-A* 0301-restricted peptide KQSSKALQR which is uniquely associated with the fusion sequence, can be detected in patients. CD8+ T cells expand in response to peptide in vitro and are able to recognise and kill CML cells that express the bcr/abl fusion peptide, illustrating its importance as a target for immunotherapy [4]. …
Literature
1.
Ali SA, Lynam J, McLean CS, Entwisle C, Louden P, Rojas JM, McArdle SEB, Li G, Mian S, Rees RC (2002) Tumour regression induced by intratumour therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte–macrophage colony–stimulating factor, correlates with antigen-specific adaptive immunity. J Immunol 168:3512PubMed
2.
Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, Jeffries WA (2000) Tap expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol 18:515PubMed
3.
Ball G, Mian S, Holding F, Allibone RO, Lowe J, Ali S, Li G, McArdle S, Ellis I, Creaser CR, Rees RC (2002) An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of potential biomarkers. Bioinformatics 18:395CrossRefPubMed
4.
Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PLR, Wang L, Christmas SE, Travers PJ, Creaser CS, Rees RC, Madrigal JA (2001) Direct evidence that leukemic cells present HLA–associated immunogenic peptides derived from the BCR–ABL b3a2 fusion protein. Blood 98:2887CrossRefPubMed
5.
Durrant LG, Parsons T, Moss R, Spendlove I, Carter G, Carr F (2001) Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses. Int J Cancer 92:414PubMed
6.
Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D (2001) Seriological detecion of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 98:629CrossRefPubMed
7.
Knights AJ, Zariou A, Rees RC, Pawelec G, Muller L (2002) Prediction of an HLA-DR binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1 (124–138): pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol Immunother 51:271PubMed
8.
Malmberg KJ, Arulampalam V, Ichihara F, Petersson M, Seki K, Andersson T, Lenkei R, Masucci G, Perrersson S, Kiessling R (2001) Inhibition of activated/memory (CD45RO(+)) T-cells by oxidative stress associated with block of NF-kappa B activation. J Immunol 167:2595PubMed
9.
Medema JP, Schuurhuis DH, Rea D, van Tongeren J, de Jong J, Bres SA, Laban S, Toes RE, Toebes M, Schumacher TN, Bladergroen BA, Ossendorp F, Kummer JA, Melief CJ, Offringa R (2001) Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T-lymphocyte-induced apoptosis: differential modulation by T-helper type 1 and type 2 cells. J Exp Med 194:657CrossRefPubMed
10.
Ostrand-Rosenberg S, Grusby MJ, Clements VK (2002) Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 165:6015
11.
Pittet MJ, Zippelius A, Valmori D, Speiser DE, Cerrottine JC, Romero P (2002) Melan-A/Mart-1-specific CD8T-cells: from thymus to tumor. Trends Immunol 23:325CrossRefPubMed
12.
Rees RC, Pawelec G, Muller L, Robins A (2002) Progress in vaccination against cancer (PIVAC) 2001. Cancer Immunol Immunother 51:58PubMed
13.
Saeboe-Larssen S, Fossberg E, Gaudernack G (2002) mRNA–based electrotransfection of human dendritic cells and induction of cytotoxic T–lymphocyte responses against the telomerase catalytic subunit (Htert). J Immunol Methods 259:191CrossRefPubMed
Metadata
Title
International conference: Progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK
Authors
Robert C. Rees
R. Adrian Robins
Graham Pawelec
Ludmila Muller
Geng Li
Ian Spendlove
Publication date
01-06-2003
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2003
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0366-3

Other articles of this Issue 6/2003

Cancer Immunology, Immunotherapy 6/2003 Go to the issue

Original Article

Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine

Original Article

Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor

Original Article

High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress

Original Article

Interferon-α and interleukin-12 gene therapy of cancer: interferon-α induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing

Original Article

A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells

Original Article

Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits